Leuco-methylthioninium

Active substance Leuco-methylthioninium
Domain Neurological disorders
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Dementia
Extended indication Alzheimer’s disease, mild-to-moderate.

Product

Proprietary name LMTX
Manufacturer TauRx
Mechanism of action Other
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Submission date 2020
Expected Registration 2021
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options donepezil, galantamine, rivastigmine.
Therapeutic value No judgement
Substantiation Leuco-methylthioninium zou een eerste disease modifying behandeling kunnen worden voor Alzheimer patiënten. Echter, er zijn twijfels over de mogelijke effectiviteit.
Duration of treatment Not found
References "The results of study TRx-237-015 suggested the hypothesis that LMTM might be effective only as monotherapy" (Wilcock et al. J Alzheimer's Disease 2018)

Expected patient volume per year

Patient volume

< 21,000

Market share is generally not included unless otherwise stated.

References http://www.levenmetalzheimer.nl/content/alzheimer/feiten-cijfers.asp, https://www.sfk.nl/publicaties/PW/2016/inzet-medicijnen-bij-dementie-loopt-terug
Additional comments In Nederland zijn 270.000 mensen dement. Hiervan hebben 160.000 tot 190.000 mensen de ziekte van Alzheimer (maximaal 70%). In totaal waren er in totaal 30.000 geneesmiddelengebruikers, die medicijnen kregen tegen dementie (SFK), uitgaande van 70% zal het maximaal gaan om 21.000 patiënten. Afhankelijk van de therapeutische waarde kan dit aandeel patiënten oplopen.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.